CAMBRIDGE, Mass., Feb. 26, 2019 /PRNewswire/
-- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a
clinical-stage immunotherapy company developing the next generation
of novel T cell receptor (TCR) therapies for patients suffering
from cancer, today announced that the underwriters of its recent
initial public offering of common stock have exercised in full
their over-allotment option and purchased an additional 750,000
shares at $15.00 per share, before
deducting underwriting discounts and commissions. The exercise of
the underwriters' over-allotment option closed on February 26, 2019, with all of the over-allotment
shares sold by TCR2. After giving effect to the sale of
the over-allotment shares, a total of 5,750,000 shares of common
stock were offered and sold in the offering.
On February 13, 2019,
TCR2 priced its initial public offering of 5,000,000
shares of common stock at $15.00 per
share. Following the closing of the exercise of the underwriters'
over-allotment option, TCR2 has received aggregate gross
proceeds, before deducting underwriting discounts and commissions
and offering expenses, of approximately $86.3 million.
Jefferies, SVB Leerink and BMO Capital Markets acted as joint
book-running managers for the offering. Wedbush PacGrow and China
Renaissance acted as co-managers for the offering.
The offering of these shares was made by means of a prospectus
forming part of the effective registration statement relating to
these shares. Copies of the prospectus may be obtained from:
Jefferies LLC, Attention: Equity Syndicate Prospectus Departments,
520 Madison Avenue, 2nd Floor, New York,
NY 10022, by phone at (877) 821-7388, or by email at
Prospectus_Department@Jefferies.com; SVB Leerink LLC, Attention:
Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, by e-mail at
syndicate@svbleerink.com, or by phone at (800) 808-7525, ext. 6132;
or BMO Capital Markets Corp., Attn: Equity Syndicate Department, 3
Times Square, 25th Floor, New York,
NY 10036, tel: (800) 414-3627, email:
bmoprospectus@bmo.com.
Important Information
A registration statement
relating to the offering has been filed with, and declared
effective by, the United States Securities and Exchange Commission
("SEC"). Copies of the registration statement can be accessed
through the SEC's website at www.sec.gov. This press release does
not constitute an offer to sell or a solicitation of an offer to
buy, nor will there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation, or sale would be
unlawful before registration or qualification under the securities
laws of that state or jurisdiction.
About TCR2 Therapeutics
TCR2 is
an innovative immunotherapy company developing the next generation
of novel T cell receptor therapies for patients suffering from
cancer.
View original
content:http://www.prnewswire.com/news-releases/tcr2-therapeutics-announces-exercise-of-over-allotment-option-300802506.html
SOURCE TCR2 Therapeutics